<Header as appropriate for mail or email letter>

Dear <Patient Name>:

Our records indicate that you may be eligible for your next colorectal cancer (CRC) screening.

Take care of yourself by screening for colorectal cancer:

* It’s often considered the most preventable, yet least prevented form of cancer 1
* When caught in early stages, it’s more treatable in about 90% of people 2\*
* Timely screening should be part of your regular health maintenance

You may recall using Cologuard ® for your last CRC screening. The American Cancer Society guidelines recommend screening again three years after a negative Cologuard result. 3 Based on the indication at the bottom of this letter, I have confirmed you are an appropriate patient to screen again with Cologuard.

As you may remember from your last screening, the Cologuard collection kit is an easy-to-use, noninvasive screening option; conveniently shipped directly to your home. No special preparation, diet, change in medication or time off is needed. When your kit arrives, plan to collect your sample when you can get it back to UPS® the same day or the next day using the prepaid UPS label.

Our office will contact you to discuss your results after we receive them from Exact Sciences Laboratories, typically within a couple weeks of when the lab receives the kit.

Most insured patients pay $0†. Cologuard is covered by Medicare and most major insurers. Nationwide, ~94% of Cologuard patients have no out-of-pocket cost for screening† If you have any questions about next steps, please contact us this week at <Provider contact information>.

**Indications and Important Risk Information**

Cologuard is intended to screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. Do not use if you have had adenomas, have inflammatory bowel disease and certain hereditary syndromes, or a personal or family history of colorectal cancer. Cologuard is not a replacement for colonoscopy in high-risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older. Cologuard performance in repeat testing has not been evaluated.

The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again. False positives and false negative results can occur. In a clinical study, 13% of people without cancer received a positive result (false positive) and 8% of people with cancer received a negative result (false negative). Rx only.

**Footnotes:**

\*Based on 5-year survival

†Exact Sciences recent estimate based on historical patient billing as of June 30, 2021. Rate of coverage varies by state and region. Exceptions for coverage may apply; only your patients' insurers can confirm how Cologuard would be covered.

**References:**

**1.** Itzkowitz SH. Incremental advances in excremental cancer detection tests. *J Natl Cancer Inst.* 2009;101(18):1225-1227. **2.** National Cancer Institute. Cancer stat facts: Colorectal cancer. Accessed July 14, 2022. https://seer.cancer.gov/statfacts/html/colorect.html. **3.** Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin.* 2018;68(4):250-281.

Cologuard is a registered trademark of Exact Sciences Corporation. All other trademarks are the properties of their respective owners. ©2022 Exact Sciences Corporation. All rights reserved. M-US-CG-02939 July 2022.

Shape

Description automatically generated with medium confidence

<INSERT HEALTH SYSTEM/PRACTICE LOGO>